CN1768754A - Application of dipyridamole in preparation of anti-malignant tumor medicine - Google Patents

Application of dipyridamole in preparation of anti-malignant tumor medicine Download PDF

Info

Publication number
CN1768754A
CN1768754A CNA2004100888616A CN200410088861A CN1768754A CN 1768754 A CN1768754 A CN 1768754A CN A2004100888616 A CNA2004100888616 A CN A2004100888616A CN 200410088861 A CN200410088861 A CN 200410088861A CN 1768754 A CN1768754 A CN 1768754A
Authority
CN
China
Prior art keywords
dipyridamole
tumor
medicine
test
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004100888616A
Other languages
Chinese (zh)
Other versions
CN100450486C (en
Inventor
周淑珍
刘国廉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2004100888616A priority Critical patent/CN100450486C/en
Priority to PCT/CN2005/001764 priority patent/WO2006047931A1/en
Publication of CN1768754A publication Critical patent/CN1768754A/en
Application granted granted Critical
Publication of CN100450486C publication Critical patent/CN100450486C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

The invention discloses the novel use of dipyridamole in preparing medicament for resisting malignant tumor, wherein the medicament can be made into the dosage forms of tablets, powder preparation, granules, oral liquids and injection. The medicament is made from Dipyridamole, medicinal starch, starch gum, beta-CD and crystalline cellulose by the weight parts ratio of 1 : 5-15, 1:0.05-0.5, 1:0.01-0.5 and 1:0.05-0.5.

Description

The application of dipyridamole in the preparation anti-malignant tumor medicine
Technical field
The present invention relates to novel application of compound, particularly relate to the application of dipyridamole in the preparation anti-malignant tumor medicine.
Background technology
At present, malignant tumor has become the commonly encountered diseases and the frequently-occurring disease of various countries, and its M ﹠ M all is ascendant trend year by year, and serious threat is to human beings'health and existence.Dipyridamole (Dipyridamole, DP) be synthetic a kind of non-anti-tumor medicine eighties in last century, be used for the treatment of coronary heart disease clinically, and be written into Pharmacopoeia of People's Republic of China (version in 2000) and American Pharmacopeia (XXI-XXIII) as the cardiovascular expander, but because of there is so-called " coronary artery stealing " phenomenon in it, the tendency that can cause bleeding when promptly share with heparin, Coumarins and fibrinolysis need not so become clinically.
The molecular formula of DP is C 24H 10N 8O 4, its chemical structural formula is suc as formula shown in the I, and molecular weight is 504.65 dalton, and is orange-yellow.DP has the little characteristics of toxicity, presses the dosage of 2.15g/Kg or 10.62g/Kg (quite clinical plan consumption 2814 times) and gives the oral DP of mice, the animal acute toxicity reaction all do not occur; Again respectively by 175,187.5 and the dosage of 93.75g/Kg, once a day, give three groups of oral DP of experimental rat, successive administration 6 months, observe and write down every index (comprising the peripheral blood phase, blood biochemical, main organs index and histological examination results such as liver function, kidney merit), there is no unusually, prove that DP does not have the long term toxicity reaction yet.
Figure A20041008886100031
(formula 1)
Summary of the invention
The inventor studies show that, dipyridamole has the effect of anti-malignant tumor, can be used widely in the medicine of preparation anti-malignant tumor.
With the dipyridamole is the anti-malignant tumor medicine of active component, when needing, can also add one or more acceptable accessories, described adjuvant comprises diluent, excipient, filler, binding agent, wetting agent, absorption enhancer, surfactant, lubricant, stabilizing agent of pharmaceutical field routine etc., also can add flavouring agent, sweeting agent and pigment etc. in case of necessity.
The anti-malignant tumor medicine that with the dipyridamole is active component can also be made multiple medicament forms such as tablet, powder, granule, oral liquid, injection except that making capsule.The medicine of above-mentioned various dosage forms all can be according to the conventional method preparation of pharmaceutical field.When adopting capsule formulation, tablet, powder, granule, the adjuvant that is added can be medical starch, dextrin, in β-CD (beta-schardinger dextrin-) and the microcrystalline Cellulose any one, dipyridamole and medical starch, dextrin, the ratio of weight and number of β-CD and microcrystalline Cellulose is respectively 1: 5-15,1: 0.05-0.5,1: 0.01-0.5,1: 0.05-0.5.
Capsule can adopt plastic-aluminum package dress, and the weight of every capsules is about 225mg, and wherein the weight of effective ingredient dipyridamole is about 25mg, and the oral consumption of being grown up was generally 75-100mg/ days, and be 10 to 20 days the course of treatment.
With the dipyridamole is that the anti-malignant tumor medicine of active component is compared with antimetabolic chemotherapeutic (as 5-fluorouracil, methotrexate, cytosine arabinoside etc.) commonly used clinically at present, and have the following advantages: 1) toxicity is little, no obvious adverse reaction; 2) curative effect is obvious, can reach 40%-96% to tumour inhibiting rates such as people's pulmonary carcinoma, ovarian cancer, gastric cancer, hepatocarcinoma; 3) have the broad spectrum anticancer activity, multiple malignant tumor and leukemia are all had in various degree antitumaous effect, wherein preferable to the curative effect of leukemia, pulmonary carcinoma, hepatocarcinoma, total effective rate can reach more than 80%; 4) can share with the antimetabolic chemotherapeutic, reaching the effect of efficacy enhancing and toxicity reducing, and can reduce the multidrug resistance of chemotherapeutic; 5) main route of administration is oral, and medication is convenient, safety, but in family and all medications during the journey; 6) its antitumaous effect has multiple pharmacological function, comprises the nucleoside salvage route of blocking-up cell nucleoside movement system, and its antitumaous effect surpasses the blocked nucleoside de novo synthesis of antimetabolic chemotherapeutic; Inducement interferon in the body, its effective dose is starkly lower than other low molecule interferon inducers; Inducing tumor cell differentiation reduces its malignant phenotype and marker enzyme activity, and the retardance cell enters the S phase and damage dna chain not; The reversing tumor cell strengthens the sensitivity to chemotherapeutic to the drug resistance of multiple medicine; Strengthen the vigor of NK cell and LAK cell, the function of human body immunity improving etc.More than these performances all demonstrate the unique distinction of dipyridamole in antitumaous effect, have broad application prospects at medical domain.
Description of drawings
Fig. 1 is a capsule formulation preparing anti-tumor medicine process chart of the present invention
The specific embodiment
Embodiment 1, adjuvant, granulation condition and packaging material are to the influence of DP
1, adjuvant is selected
The content of main component DP in capsule seldom, thereby need use the adjuvant filling, this test mixes β-CD, medical starch, dextrin and microcrystalline Cellulose respectively with DP, under the condition of high light (4900LX), high temperature (60 ℃), high humidity (humidity is 92%), investigate the influence of above-mentioned adjuvant to DP, concrete steps are as follows:
Take by weighing DP2.5g, respectively with above-mentioned each 22.5g mixing of four kinds of adjuvants, every part amounts to 25g, is divided into three aliquots again, puts into lighting box (4900LX), calorstat (60 ℃) respectively and contains saturated KNO at every turn 3(humidity is 92%) accelerates the failure in the exsiccator of solution, puts into DP raw material (contrast) simultaneously, measures DP content, and result of the test is as shown in table 1:
Table 1 adjuvant is to the result of the test of DP influence
Condition Detection Starch Dextrin Microcrystalline Cellulose β-CD The DP raw material
Original Outward appearance Orange red Orange red Orange red Orange red Yellow
DP content (%) 9.55 9.73 9.64 9.79 100
Heating (60 ℃) Outward appearance Orange-yellow Orange-yellow Orange-yellow Orange-yellow Yellow
(the 3rd day) DP content (%) 9.63 9.50 9.60 9.84 100.29
Strong illumination (4900LX) Outward appearance Orange red Orange red Orange red Orange red Yellow
(the 3rd day) DP content (%) 9.58 9.76 9.68 9.83 100.48
High humidity (RT92%) Outward appearance Orange red Orange red Orange red Orange red Yellow
(the 3rd day) DP content (%) 9.83 9.71 9.57 9.80 99.47
By the test that accelerates the failure, show that selected adjuvant does not have significant protective effect to the variation of DP itself, explanation will make medicine stable, need take lucifuge, secluding air and refrigerated condition.
2, dry-pressing granulation condition determines
The preparation technology who with DP is the capsule-type medicine of active component adopts dry method directly to suppress granulating.The factor that influences the dry-pressing granulate quality is a lot, comprises supplementary product kind, water content and operating pressure etc.Two kinds of adjuvants of this experimental selection starch and β-CD are made granule under different moisture content and pressure condition, and its particulate density, flowability etc. are tested, and are that medium is measured particulate disintegration with water, and the result is as shown in table 2:
Table 2 is that medium is measured particulate density, flowability and disintegration result of the test with water
Supplementary product kind Pressure (Kg/cm 2) Moisture (%) Measurement result
Bulk density (g/ml) Mobile (angle of repose) Disintegration (minute)
β-CD 40 5-6 0.72 30 7.3
3-4 0.62 31 7.9
50 5-6 0.73 29 8.1
3-4 0.68 30 8.0
Starch 40 5-6 0.62 30 7.5
3-4 0.57 31 7.4
50 5-6 0.62 30 7.9
3-4 0.60 30 7.9
The result shows that the compactibility of β-CD is good, and under same pressure and moisture condition, granule is tightr, and starch is at pressure 50Kg/cm 2, moisture is under the condition of 5%-6%, and its density and flowability are all better, the two obtained particulate disintegration no significant difference.
3, drug packaging is to the influence of its stability
Because DP is all responsive to temperature, air humidity and illumination condition, thereby to take the measure of airtight, secluding air and lucifuge be the key factor that guarantees curative effect of medication.This experiment adopts dry method with β-CD and starch filled capsule, moulds the aluminum film, is packaged into bag, it is placed temperature respectively is under 60 ℃ and 40 ℃, and humidity is in two kinds of environment of 92%, to be contrast with unpacked identical capsule, the experiment that accelerates the failure, the result is as shown in table 3:
Table 3 drug packaging is to the influence of DP stability
Group Supplementary product kind Initial content (g) 60℃，RT92％ 40℃，RT92％
7 days 15 days 15 days 30 days
Experimental group Starch DP content (%) 9.72 9.68 9.65 9.68 9.68
β-CD DP content (%) 10.02 9.91 9.60 10.05 9.96
Matched group Starch DP content (%) 9.72 9.67 9.64 9.67 9.67
β-CD DP content (%) 10.02 10.00 9.90 9.87 9.91
The result shows that packaging material can reduce the degradation speed of medicine greatly, plays the good protective effect of medicine.(starch, β-CD) are as the filler of the DP no significant difference that influences to DP for two kinds of adjuvants.But relatively costly because of the price of β-CD, thereby to select starch among the following embodiment of the present invention for use be the adjuvant that the present invention uses.
The preparation of embodiment 2, DP capsule
1, the prescription of capsule: DP 25g, starch 200g;
Make 1000 capsules, every heavy 225mg, every contains DP11.1%;
2, as shown in Figure 1, to prepare the capsular concrete steps of antitumor DP as follows in the present invention:
1) starch is dried to water content under 80 ℃-90 ℃ and is 3%-5%, standby;
2) getting dipyridamole and mix with dried starch, fully stir, is orange-yellow to mixed powder, takes out;
3) use dry granulation;
4) filled capsules, polishing;
5) carrying out outer package with two aluminum gets final product.
The anti-tumor experiment of embodiment 3, DP
1, cell in vitro experiment
Select people's pulmonary carcinoma (A549), people's hepatocarcinoma (BEL-7402), people's gastric cancer (BCK-823) and four kinds of tumor strains of human leukemia (HL60) for use, the positive contrast medicine of tegafur (T-207) detects the inhibitory action of the DP of different meterings to tumor cell in vitro.During experiment, with 0.1N HCl dissolving DP, reuse HK liquid (purchasing of raw materials is from the Beijing Chemical Plant) is diluted to required cultivating system Chinese medicine final concentration and is respectively 0,20,40,80 μ g/ml, the final concentration of T-207 is respectively 0.3,0.6,1.2 μ g/ml, the not dosing of blank group, with volume about 1000 left and right sides cells of inoculation in the square vase of 30ml, dosing behind 37 ℃ of cultivation 24h, cultivated again 7-8 days, sampling, with the dyeing of crystal violet dye liquor, statistics contains clone's number of 50 above cell masses, calculate its cloning efficiency (%) and suppression ratio (%) respectively by following formula, experimental result is as shown in table 4:
Figure A20041008886100071
The DP of table 4 various dose is to the suppression ratio result of the test of tumor strain
Group Dosage (μ g/ml) To the suppression ratio of four kinds of tumor strains (x ± SD)
A549 BCK-823 BEL-7402 HL60
DP 20 70.4±2.24 51.1±26.12 74.9±22.09 61.8±10.86
40 82.1±2.58 73.8±19.0 84.4±14.18 84.8±21.02
80 90.2±5.24 89.0±12.30 92.8±5.86 94.1±30.12
T-207 0.3 59.30±11.56 72.3±3.88 65.1±31.84 39.0±20.80
0.6 66.8±12.02 78.1±3.00 73.9±25.83 46.7±30.11
1.2 79.3±1.67 89.0±1.62 83.6±24.31 63.1±27.80
The result shows, DP is in the experimental concentration scope, four strain human cancer cells all there is good inhibitory effect, under same concentrations, to the suppression ratio and the no significant difference (ρ＞0.05) of each tumor strain, and be higher than the suppression ratio (remove heavy dose of suppression ratio to BCK-823 tumor strain) of positive control drug tegafur to the tumor strain.
2, tumor bearing nude mice test
Select Balb/c tumor bearing nude mice test model for use, 70 every batch, be divided into blank group, positive drug control group (T-20710.0mg/ml) and three dosage groups of DP (20,80,200mg/Kg), with batch same sex of test, about body weight 20g, raise under aseptic condition, inoculate the oncocyte number is 10 at every turn 6-10 7Individual/only, grew the tumor piece in subcutaneous injection 7-8 days, select of the nude mice test of tumor mass diameter greater than 1cm, every day, by above-mentioned dosed administration once successive administration 30 days was parallelly done three tests, the body weight of viewing test animal, appetite, general activity situation, measure tumor after living extremely and heavily reach diameter, the indexs such as weight, organ index and histopathology thereof of each main organs (comprising the heart, liver,kidney,spleen, stomach etc.), experimental result is shown in table 5-6:
The tumour inhibiting rate statistics of three batches of tumor bearing nude mice tests of table 5
Group Dosage Tumor body volume The tumor body
(mg/Kg) Minification (%) Meansigma methods ± SD Tumour inhibiting rate (%) Meansigma methods ± SD
BCK-823 Tegafur 10 8.08，68.97 38.52±43.06 38.65，75.58 56.22±27.39
DP 20 0，15.43 7.72±10.91 30.00，25.35 27.68±3.29
80 29.36，59.00 44.18±20.96 51.51，61.43 56.47±7.01
200 50.69，68.01 59.25±12.25 74.79，69.36 72.08±3.84
A549 Tegafur 10 79.22，79.54，90.22 82.99±6.26 80.70，87.16，89.81 88.56±1.33
DP 20 70.13，82.95，79.35 77.48±6.61 80.87，82.57，87.04 83.49±3.19
80 84.43，77.27，95.65 85.78±9.27 85.22，84.47，95.37 88.35±6.09
200 75.32，73.86，92.39 80.52±10.30 81.74，79.82，87.96 83.17±4.26
A2780 Tegafur 10 51.36，18.90，41.84 37.37±16.69 55.82，32.54，45.56 44.64±11.67
DP 20 61.14，5.51，20.57 29.07±28.77 60.36，0，20.12 26.85±30.73
80 44.55，32.28，39.72 38.85±6.18 43.59，23.67，49.70 38.99±13.61
200 45.45，1.57，61.70 36.24±31.11 44.18，0，76.92 40.37±38.60
Table 6 couple A2780 tumor bearing nude mice tumor body diameter and pathological examination result
Group Dosage (mg/Kg) Number of animals The tumor growth situation Cancerous cell is invaded profit, transfer case
Tumor nodule (＜1cm) No tuberosity Muscle is invaded profit Internal organs shift
The blank group 0 7 0 0 5 0
T-207 100 7 1 1 2 0
20 7 1 0 2 0
DP 40 7 0 2 2 0
200 7 2 0 2 1
Annotate: if the tumor nodule diameter shows that then the tumor body obviously dwindles less than 1cm; No tuberosity shows the tumor body situation that disappears.
Above-mentioned animal test results shows: DP is to A549, BCK-823, and A2780 three-type-person cancer all has tumor killing effect preferably.Wherein higher to tumor body minification and the tumour inhibiting rate of A549, approach T-207 positive control drug level (83%-88.6%), but no significant difference between each dosage group; To the strain of BCK-823 tumor, except that the tumor minification (7.22%) of 20mg/Kg dosage group and tumour inhibiting rate (27.7%) are low, above-mentioned two indexs of all the other two dosage groups all increase with the increase of dosage, and surpass the level (38.5%-56.2%) of T-207 positive controls; A2780 has been obtained same effect: with the increase of dosage, tumor minification and tumour inhibiting rate increase, and are equivalent to T-207 level (37.4%-55.8%).A2780 tumor bearing nude mice internal organs pathological examination is the result show, blank group tumor body diameter is all above 1cm, do not see the tumor body phenomenon that disappears, and the tumor body diameter of T-207 and DP group is generally less than 1cm, T-207 and DP dosage group have 1 animal and 2 animals not to see the tumor piece respectively, and the blank group has the cancerous cell of 5 animals to have muscle to invade the profit phenomenon, each group of T-207 and DP is individual to have the cancerous cell of 2 animals to have muscle to invade the profit phenomenon, but except that the high dose group of DP has the internal organs of the generation cancerous cell of 1 animal shift, all the other there is no cancerous cell generation internal organs and shift, and illustrate that DP can effectively prevent the diffusion of cancerous cell.
3, toxicity, toxicity test
1) general pharmacology test
Adopt cat and rat test model (available from Military Medical Science Institute), and the usefulness cat (24, female, hero half and half, body weight 2.4-3.7Kg is divided into 4 groups, 6 every group, dosage is respectively 30,60,120mg/Kg) test, observe DP to influences such as blood pressure, respiratory frequency, hearts rate; With Mus (40, female, male half and half, body weight 18-20g is divided into 4 groups, 10 every group, dosage is respectively 60,120,240mg/Kg) test, observe the influence of DP to rat autonomic activities situation.Result of the test shows that three dosage groups of DP all do not have obvious influence to blood pressure, respiratory frequency and amplitude, heart rate, the rhythm of the heart of cat, and the autonomic activities number of times of rat is not had obvious influence yet.
2) acute toxicity test of DP
Adopt mouse test model (available from Military Medical Science Institute), (40 of Kunming mouses, be divided into blank group and DP group, every group each 20), dosage 10.63g/Kg is obeyed in once maximum filling appetite, is equivalent to 2834 times of clinical plan consumption (3.75mg/Kg), observes 28 days, comprise mice body weight gradient, active situation and death condition, result of the test is as shown in table 7:
Table 7 DP is to the The acute toxicity tests of mice
Group Sex Number of animals Body weight (g) before the administration 28 days body weight after the administration Advance long and active situation Death toll
Body weight (g) Rate of increase (%)
The blank group Female 10 19.0±0.90 26.7±1.11 34.76 Normally 0
Male 10 20.9±0.57 32.4±1.68 44.06 Normally 0
The DP group Female 10 18.5±0.73 26.4±1.59 36.29 Normally 0
Male 10 20.2±0.91 30.2±0.72 45.16 Normally 0
Result of the test shows, once irritates appetite clothes maximum dosage-feeding 10.63g/Kg, be equivalent to 2834 times of clinical administration amount, but acute toxic reaction does not take place all experimental animal, and the rate of increase of rarely seen male mice body weight is higher than female mice, illustrates that the toxicity of DP is very little.
3) long term toxicity test
Adopt the rat test model, SPF level Wistar rat is (available from Military Medical Science Institute, 176, body weight 90-100g), be divided into three dosage groups (93.75 of blank group and DP, 187.5 and 375mg/Kg), totally four groups, every group of 44 rats, the normal saline that the blank group deturs talis dosis, every day gastric infusion once, serve on 6 months, observation index comprises the general physical signs and the peripheral blood phase of experimental animal, blood biochemical, liver function, the variation of main organs organ indexes such as kidney merit and histopathological examination inspection etc., result of the test shows, the oral various dose of rat (93.75,187.5 DP and 375mg/Kg), be respectively 25 of clinical application amount, 50 and 100 times, successive administration 6 months does not see that every index is unusual, yet no significant difference (ρ＞0.05) between the various dose group, illustrate that it is safe taking DP for a long time, avirulent accumulative effect.
The clinical trial of embodiment 4, DP capsule
Carry out Preliminary Clinical Observation after the cancer patient who is diagnosed as middle and advanced stage being taken the DP capsule of embodiment 2 preparation, comprise curative effect and untoward reaction etc., successively the 340 routine malignant tumor patients of kind more than 10 such as pulmonary carcinoma (various), hepatocarcinoma, gastric cancer, intestinal cancer, leukemia, ovarian cancer, lymphatic cancer, nasopharyngeal carcinoma are observed, the 204 routine cases that wherein record material is more complete are carried out preliminary analysis, and the result is as shown in table 8:
The clinical test results of table 8 DP capsule
The sick kind Case load CR+PR NC or PD
The example number Account for and analyze routine hundreds of proportions by subtraction The example number Account for and analyze routine hundreds of proportions by subtraction
Pulmonary carcinoma 92 69 75.0 23 25.0
Gastric cancer 49 41 83.7 8 16.3
Hepatocarcinoma 45 38 84.4 7 15.6
Intestinal cancer 22 18 81.8 4 18.2
Leukemia 11 11 100.0 0 0
Ovarian cancer 11 10 90.9 1 0.09
Annotate: for alleviating fully, PR is that part is alleviated according to general international standard: CR, and NC is a no change, and PD is for increasing.
Result of the test shows that DP all has curative effect preferably to multiple cancer, and wherein the curative effect to leukemia and ovarian cancer is particularly outstanding, the curative effect of all the other diseases is all on same level, total effective rate reaches more than 64.7%, and does not see obvious adverse reaction, rarely seen back one property crossed stomach discomfort of taking medicine.

Claims (6)

1, the application of dipyridamole in the preparation anti-malignant tumor medicine.
2, application according to claim 1 is characterized in that: the dosage form of described medicine is capsule, tablet, powder, granule, oral liquid or injection.
3, application according to claim 2 is characterized in that: be added with medical starch in described capsule, tablet, powder or the granule, the ratio of weight and number of dipyridamole and medical starch is 1: 5-15.
4, application according to claim 2 is characterized in that: be added with dextrin in described capsule, tablet, powder or the granule, the ratio of weight and number of dipyridamole and dextrin is 1: 0.05-0.5.
5, application according to claim 2 is characterized in that: be added with β-CD in described capsule, tablet, powder or the granule, the ratio of weight and number of dipyridamole and β-CD is 1: 0.01-0.5.
6, according to claim 2 or 3 or 4 or 5 described application, it is characterized in that: described medicine adopts plastic-aluminum package dress.
CNB2004100888616A 2004-11-05 2004-11-05 Application of dipyridamole in preparation of anti-malignant tumor medicine Expired - Fee Related CN100450486C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CNB2004100888616A CN100450486C (en) 2004-11-05 2004-11-05 Application of dipyridamole in preparation of anti-malignant tumor medicine
PCT/CN2005/001764 WO2006047931A1 (en) 2004-11-05 2005-10-26 The use of dipyridamole in manufacturing the anti-malignant tumor medicines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100888616A CN100450486C (en) 2004-11-05 2004-11-05 Application of dipyridamole in preparation of anti-malignant tumor medicine

Publications (2)

Publication Number Publication Date
CN1768754A true CN1768754A (en) 2006-05-10
CN100450486C CN100450486C (en) 2009-01-14

Family

ID=36318878

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100888616A Expired - Fee Related CN100450486C (en) 2004-11-05 2004-11-05 Application of dipyridamole in preparation of anti-malignant tumor medicine

Country Status (2)

Country Link
CN (1) CN100450486C (en)
WO (1) WO2006047931A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198150A (en) * 2010-03-26 2011-09-28 中国医学科学院医药生物技术研究所 Antitumor drug with double active components and application thereof
CN104546752A (en) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 Dipyridamole composition freeze-drying tablet and preparation method thereof
WO2018019284A1 (en) * 2016-07-28 2018-02-01 Realinn Life Science Limited Compounds for enhancing bax/bcl-2 expression and activity and therapeutic use thereof
CN114762691A (en) * 2021-01-12 2022-07-19 中国科学院上海药物研究所 Application of dipyridamole in anti-tumor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4308286A1 (en) 2021-03-16 2024-01-24 Symrise AG Active substance capsules
WO2023092462A1 (en) * 2021-11-26 2023-06-01 中国科学院深圳先进技术研究院 Use of dipyridamole in inhibiting mcl-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003330C1 (en) * 1989-12-15 1993-11-30 Виктор Николаевич Чернов Method for treatment of mammary gland carcinoma

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198150A (en) * 2010-03-26 2011-09-28 中国医学科学院医药生物技术研究所 Antitumor drug with double active components and application thereof
CN102198150B (en) * 2010-03-26 2013-11-06 中国医学科学院医药生物技术研究所 Antitumor drug with double active components and application thereof
CN104546752A (en) * 2014-12-25 2015-04-29 海南卫康制药(潜山)有限公司 Dipyridamole composition freeze-drying tablet and preparation method thereof
WO2018019284A1 (en) * 2016-07-28 2018-02-01 Realinn Life Science Limited Compounds for enhancing bax/bcl-2 expression and activity and therapeutic use thereof
CN114762691A (en) * 2021-01-12 2022-07-19 中国科学院上海药物研究所 Application of dipyridamole in anti-tumor

Also Published As

Publication number Publication date
CN100450486C (en) 2009-01-14
WO2006047931A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CN103319479A (en) Rheinic acid berberine ion pair compound, preparation method and applications
CN1237976C (en) Bite spiramycin and its use in anti inflammatory disease
CN100450486C (en) Application of dipyridamole in preparation of anti-malignant tumor medicine
CN104586828A (en) Application of chlorogenic acid in preparation of drug for treating choriocarcinoma
CA3079031C (en) Formulation containing a-decarbonized-5-alpha androstane compound for increasing white blood cell and use thereof
CN101507747B (en) Preparation method of astragalus total-saponin sodium chloride injector
CN1686184A (en) Soft capsule using dendrobium as raw material and its preparation method
CN102961340A (en) Nanoscale insulin and preparation method thereof
CN1278676C (en) Curcumin injection and method for preparing the same
CN101190210B (en) Application of triacontanol in preparing anti-cancer medicine
CN101721612B (en) Chinese medicinal composition for raising leucocytes and preparation method and application thereof
CN1287808C (en) Ginkgo leaf extract composition
CN101537013A (en) Application of nanometer polysaccharide for preparing antineoplastic medicament
CN100337625C (en) Anastrozole dispersed tablet formulation
CN101062040B (en) Stable type cucurbitacin liquid formula and the agent thereof
CN100588405C (en) Deoxyuridine powder injection and preparation method thereof
CN1305471C (en) Use of sophoridine oxide in preparing anticancer medicine
CN105687225B (en) A kind of pharmaceutical composition for treating irritable bowel syndrome and its preparation method and application
CN103316017A (en) Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes
CN1172702C (en) Sugar-free erigeron breviscapus granule and its prepn and application
CN102920746B (en) Worm grass and Chinese blister beetle composition, enteric preparation, and application and preparation thereof
CN101342143A (en) Preparation of antineoplastic drug docetaxel injection
CN101249149B (en) Pharmaceutical combination for intestinal tract hemostasia and method of preparing the same
CN100482264C (en) Shenling Chinese medicine preparation for strengthening body resistance
CN105832771B (en) A kind of drug and preparation method thereof for treating gastrointestinal candidiasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090114

Termination date: 20121105